Selected research
Industry Growth & Trends
Global Platinum Anti-tumor Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Platinum Anti-tumor Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Platinum Anti-tumor Drugs market include Teva, Sun Pharma, Sanofi, Novartis, Pfizer, Hengrui Medicine, Yi Bai Pharmaceutical, Viatris and SK Chemicals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Platinum Anti-tumor Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Platinum Anti-tumor Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Platinum Anti-tumor Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Platinum Anti-tumor Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Platinum Anti-tumor Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Platinum Anti-tumor Drugs Market by Company
Teva
Sun Pharma
Sanofi
Novartis
Pfizer
Hengrui Medicine
Yi Bai Pharmaceutical
Viatris
SK Chemicals
Qilu Pharmaceutical
Dr Reddy's Laboratories
Debiopharm
ASK Pharma
Accord Healthcare
Platinum Anti-tumor Drugs Segment by Type
Oxaliplatin
Carboplatin
Cisplatin
Other
Platinum Anti-tumor Drugs Segment by Application
Ovarian Cancer
Lung Cancer
Colorectal Cancer
Other
Platinum Anti-tumor Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum Anti-tumor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum Anti-tumor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum Anti-tumor Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Platinum Anti-tumor Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oxaliplatin
- Carboplatin
- Cisplatin
- Other
Applications
- Ovarian Cancer
- Lung Cancer
- Colorectal Cancer
- Other
Companies covered
- Teva
- Sun Pharma
- Sanofi
- Novartis
- Pfizer
- Hengrui Medicine
- Yi Bai Pharmaceutical
- Viatris
- SK Chemicals
- Qilu Pharmaceutical
- Dr Reddy's Laboratories
- Debiopharm
- ASK Pharma
- Accord Healthcare
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Platinum Anti-tumor Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Platinum Anti-tumor Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Platinum Anti-tumor Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Platinum Anti-tumor Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Platinum Anti-tumor Drugs Market Size (2021-2032)
- 1.5.1 North America Platinum Anti-tumor Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Platinum Anti-tumor Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Platinum Anti-tumor Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Platinum Anti-tumor Drugs Market Size Growth Rate (2021-2032)
2 Platinum Anti-tumor Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Oxaliplatin
- 2.1.2 Carboplatin
- 2.1.3 Cisplatin
- 2.1.4 Other
- 2.2 Global Platinum Anti-tumor Drugs Market Size by Type
- 2.2.1 Global Platinum Anti-tumor Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Platinum Anti-tumor Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Platinum Anti-tumor Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Platinum Anti-tumor Drugs Market Size by Regions
- 2.3.1 North America Platinum Anti-tumor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Platinum Anti-tumor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Platinum Anti-tumor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Platinum Anti-tumor Drugs Market Size Breakdown by Type (2021-2026)
3 Platinum Anti-tumor Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Ovarian Cancer
- 3.1.2 Lung Cancer
- 3.1.3 Colorectal Cancer
- 3.1.4 Other
- 3.2 Global Platinum Anti-tumor Drugs Market Size by Application
- 3.2.1 Global Platinum Anti-tumor Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Platinum Anti-tumor Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Platinum Anti-tumor Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Platinum Anti-tumor Drugs Market Size by Regions
- 3.3.1 North America Platinum Anti-tumor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Platinum Anti-tumor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Platinum Anti-tumor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Platinum Anti-tumor Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Platinum Anti-tumor Drugs Industry Trends
- 4.2 Platinum Anti-tumor Drugs Industry Drivers
- 4.3 Platinum Anti-tumor Drugs Industry Opportunities and Challenges
- 4.4 Platinum Anti-tumor Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Platinum Anti-tumor Drugs Revenue (2021-2026)
- 5.2 Global Platinum Anti-tumor Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Platinum Anti-tumor Drugs Key Company Headquarters & Area Served
- 5.4 Global Platinum Anti-tumor Drugs Company, Product Type & Application
- 5.5 Global Platinum Anti-tumor Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Platinum Anti-tumor Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Platinum Anti-tumor Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Platinum Anti-tumor Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva
- 6.1.1 Teva Company Information
- 6.1.2 Teva Business Overview
- 6.1.3 Teva Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Platinum Anti-tumor Drugs Product Portfolio
- 6.1.5 Teva Recent Developments
- 6.2 Sun Pharma
- 6.2.1 Sun Pharma Company Information
- 6.2.2 Sun Pharma Business Overview
- 6.2.3 Sun Pharma Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sun Pharma Platinum Anti-tumor Drugs Product Portfolio
- 6.2.5 Sun Pharma Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sanofi Platinum Anti-tumor Drugs Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novartis Platinum Anti-tumor Drugs Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Platinum Anti-tumor Drugs Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Hengrui Medicine
- 6.6.1 Hengrui Medicine Company Information
- 6.6.2 Hengrui Medicine Business Overview
- 6.6.3 Hengrui Medicine Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio
- 6.6.5 Hengrui Medicine Recent Developments
- 6.7 Yi Bai Pharmaceutical
- 6.7.1 Yi Bai Pharmaceutical Company Information
- 6.7.2 Yi Bai Pharmaceutical Business Overview
- 6.7.3 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- 6.7.5 Yi Bai Pharmaceutical Recent Developments
- 6.8 Viatris
- 6.8.1 Viatris Company Information
- 6.8.2 Viatris Business Overview
- 6.8.3 Viatris Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Viatris Platinum Anti-tumor Drugs Product Portfolio
- 6.8.5 Viatris Recent Developments
- 6.9 SK Chemicals
- 6.9.1 SK Chemicals Company Information
- 6.9.2 SK Chemicals Business Overview
- 6.9.3 SK Chemicals Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 SK Chemicals Platinum Anti-tumor Drugs Product Portfolio
- 6.9.5 SK Chemicals Recent Developments
- 6.10 Qilu Pharmaceutical
- 6.10.1 Qilu Pharmaceutical Company Information
- 6.10.2 Qilu Pharmaceutical Business Overview
- 6.10.3 Qilu Pharmaceutical Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- 6.10.5 Qilu Pharmaceutical Recent Developments
- 6.11 Dr Reddy's Laboratories
- 6.11.1 Dr Reddy's Laboratories Company Information
- 6.11.2 Dr Reddy's Laboratories Business Overview
- 6.11.3 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio
- 6.11.5 Dr Reddy's Laboratories Recent Developments
- 6.12 Debiopharm
- 6.12.1 Debiopharm Company Information
- 6.12.2 Debiopharm Business Overview
- 6.12.3 Debiopharm Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Debiopharm Platinum Anti-tumor Drugs Product Portfolio
- 6.12.5 Debiopharm Recent Developments
- 6.13 ASK Pharma
- 6.13.1 ASK Pharma Company Information
- 6.13.2 ASK Pharma Business Overview
- 6.13.3 ASK Pharma Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 ASK Pharma Platinum Anti-tumor Drugs Product Portfolio
- 6.13.5 ASK Pharma Recent Developments
- 6.14 Accord Healthcare
- 6.14.1 Accord Healthcare Company Information
- 6.14.2 Accord Healthcare Business Overview
- 6.14.3 Accord Healthcare Platinum Anti-tumor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio
- 6.14.5 Accord Healthcare Recent Developments
7 North America
- 7.1 North America Platinum Anti-tumor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 7.3 North America Platinum Anti-tumor Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Platinum Anti-tumor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 8.3 Europe Platinum Anti-tumor Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Platinum Anti-tumor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Platinum Anti-tumor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 10.3 South America Platinum Anti-tumor Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Platinum Anti-tumor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Platinum Anti-tumor Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst